{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:35:42Z","timestamp":1762252542360},"reference-count":45,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.03.019","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T12:30:52Z","timestamp":1492432252000},"page":"5481-5486","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout"],"prefix":"10.1016","volume":"35","author":[{"given":"Stella S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Phy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Peden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sheng-Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.019_b0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/14760584.2014.885841","article-title":"Ebola virus vaccines: an overview of current approaches","volume":"13","author":"Marzi","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.019_b0010","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.03.019_b0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.019_b0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine \u2013 preliminary report","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.03.019_b0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1473-3099(15)00222-4","article-title":"Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort","volume":"15","author":"Ledgerwood","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.019_b0030","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.019_b0035","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0040","article-title":"A monovalent chimpanzee adenovirus ebola vaccine \u2013 preliminary report","volume":"1\u201310","author":"Rampling","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.03.019_b0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.019_b0050","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2011.08.012","article-title":"Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies","volume":"423","author":"Higa","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.03.019_b0060","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1128\/JVI.00164-09","article-title":"Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy","volume":"83","author":"Porotto","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jviromet.2009.11.004","article-title":"Study of Andes virus entry and neutralization using a pseudovirion system","volume":"163","author":"Ray","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.03.019_b0070","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","article-title":"Recombinant vesicular stomatitis viruses from DNA","volume":"92","author":"Lawson","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.03.019_b0075","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1073\/pnas.93.21.11359","article-title":"Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles","volume":"93","author":"Schnell","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.03.019_b0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/JVI.01860-12","article-title":"A chimeric vesiculo\/alphavirus is an effective alphavirus vaccine","volume":"87","author":"Chattopadhyay","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0085","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.03246-14","article-title":"A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine","volume":"89","author":"Ryder","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0090","first-page":"272","article-title":"Development and applications of VSV vectors based on cell tropism","volume":"2","author":"Tani","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0095","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against lassa and ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.019_b0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-59745-181-9_23","article-title":"Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins","volume":"454","author":"Fukushi","year":"2008","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0110","first-page":"2651","article-title":"A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus","volume":"159","author":"Cheresiz","year":"2014","journal-title":"Adv Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2009.04.037","article-title":"A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein","volume":"160","author":"Kaku","year":"2009","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.03.019_b0120","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jviromet.2011.11.003","article-title":"Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase","volume":"179","author":"Kaku","year":"2012","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.03.019_b0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2008.03.002","article-title":"SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector","volume":"376","author":"Kapadia","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.03.019_b0130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virol.2005.06.016","article-title":"Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine","volume":"340","author":"Kapadia","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.03.019_b0135","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/v4102097","article-title":"Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers","volume":"4","author":"Fukushi","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2017.03.019_b0140","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1099\/vir.0.80955-0","article-title":"Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein","volume":"86","author":"Fukushi","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0145","doi-asserted-by":"crossref","first-page":"e56023","DOI":"10.1371\/journal.pone.0056023","article-title":"Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR","volume":"8","author":"Teferedegne","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.019_b0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1743-422X-10-195","article-title":"A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment","volume":"10","author":"Varada","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2017.03.019_b0155","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1016\/j.vaccine.2015.10.110","article-title":"RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells","volume":"33","author":"Wang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.019_b0160","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/femsre\/fuw010","article-title":"Neglected filoviruses","volume":"40","author":"Burk","year":"2016","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.03.019_b0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0140-6736(90)90737-P","article-title":"Preliminary report: isolation of ebola virus from monkeys imported to USA","volume":"335","author":"Jahrling","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.019_b0170","first-page":"1229","article-title":"Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA","volume":"159","author":"Kuhn","year":"2014","journal-title":"Adv Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.03.019_b0180","doi-asserted-by":"crossref","first-page":"12781","DOI":"10.1128\/JVI.00794-11","article-title":"Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus","volume":"85","author":"Brown","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0185","doi-asserted-by":"crossref","first-page":"e0137786","DOI":"10.1371\/journal.pone.0137786","article-title":"Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against Lethal Zaire and Sudan Ebolaviruses","volume":"10","author":"Bounds","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.019_b0190","doi-asserted-by":"crossref","first-page":"24897","DOI":"10.1038\/srep24897","article-title":"Production of potent fully human polyclonal antibodies against ebola zaire virus in transchromosomal cattle","volume":"6","author":"Dye","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.03.019_b0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jviromet.2007.02.007","article-title":"Quantitative multiplex assay for simultaneous detection of the Indiana serotype of vesicular stomatitis virus and HIV gag","volume":"143","author":"Coleman","year":"2007","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.03.019_b0200","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of zaire ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.03.019_b0205","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/v4040447","article-title":"Structural basis for differential neutralization of ebolaviruses","volume":"4","author":"Bale","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2017.03.019_b0210","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.sbi.2009.05.004","article-title":"Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it","volume":"19","author":"Lee","year":"2009","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0215","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/femsre\/fuv031","article-title":"Ebolavirus comparative genomics","volume":"39","author":"Jun","year":"2015","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.03.019_b0220","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nsmb.2150","article-title":"A shared structural solution for neutralizing ebolaviruses","volume":"18","author":"Dias","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2017.03.019_b0225","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1128\/JVI.00101-16","article-title":"Chimeric filoviruses for identification and characterization of monoclonal antibodies","volume":"90","author":"Ilinykh","year":"2016","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T15:56:08Z","timestamp":1601913368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":45,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17303250"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}